A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.
about
Outer membrane vesicles as platform vaccine technologyMeningococcal B vaccine and the vision of a meningitis free worldBacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic DiseasesReverse vaccinology 2.0: Human immunology instructs vaccine antigen designPrevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infectionProtein Crystallography in Vaccine Research and DevelopmentMolecular Basis of Ligand-Dependent Regulation of NadR, the Transcriptional Repressor of Meningococcal Virulence Factor NadAEmerging experience with meningococcal serogroup B protein vaccines.Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United StatesCharacteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).Meningococcal B vaccination: real-world experience and future perspectives.Development and evaluation of a dipstick diagnostic test for Neisseria meningitidis serogroup XWill Genome Analysis Elucidate Evolution, Global Transmission and Virulence of Neisseria Meningitidis Lineages?Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage.[Meningococcus B: control of two outbreaks by vaccination]Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in CombinationImmunogenicity of a Meningococcal B Vaccine during a University Outbreak.Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.The role of structural proteomics in vaccine development: recent advances and future prospects.Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity.Paediatricians require more information before they routinely co-administer the meningococcal B vaccine with routine infant vaccines.Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.The incidence of Kawasaki disease after vaccination within the UK pre-school National Immunisation Programme: an observational THIN database study.A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: a phase 3, open-label, randomized study.Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes.Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.Meningococcal vaccination in pregnancy.Structures of NHBA elucidate a broadly conserved epitope identified by a vaccine induced antibody
P2860
Q26766539-31EFBFBD-27CC-4CC2-BDB5-38C3999CC82FQ26770696-CECFC237-A055-4420-A3AB-BF63BB95B211Q26778773-4CB5AE19-17D5-4714-8A42-A47E8CCE814AQ28075274-6206B7FC-1FC1-406D-B139-E6CE58850FFAQ28080522-70CE6C99-163E-4198-AFB6-A8BFB18B54E3Q28087528-82212B30-0399-47C7-8B0C-557C33A503A2Q28551548-D9ED75CE-CC26-423B-869A-5DAEF30C8090Q30234958-524FED4F-D9BD-4E9E-BB7F-02ADA4621E9FQ30235072-08548257-4B57-4B88-8E79-ADA9F78A0B84Q30248749-9598D506-471D-4DC5-9D7A-784CD92239BCQ30249575-D4BB8AE8-E462-40A3-BBA1-64FF1F6DA91CQ34983112-62F4F2DC-A032-4B86-83D1-B13D0DDB7602Q35795084-05C41F83-D824-404E-9154-F7A6782D7B78Q36254505-EDC3A4CC-7287-4A50-BD97-4AB951B6AA5DQ36478336-55FE70C2-85E8-488F-A974-589E7A4AEBB1Q36764403-B5939254-74FA-45EA-A1C7-FA6FE5FCDFF9Q37192707-B2807708-A5B0-45E4-98AE-12A7B7637CD3Q38363907-B1FB772F-DE39-4EFB-B909-C4D6A7AB739FQ38682335-D87F7F20-FCBB-4561-BF53-059F5F450183Q38812268-055E1D31-9984-4710-BE39-2D41AFAE2D69Q39093233-9E1D9E4B-1143-4835-A902-5A80B0556C63Q39567592-E16C8A87-E78F-4EA1-ABBC-2ABD971DBCF6Q40172533-05573D34-85A8-4257-8379-372D634448C1Q40178578-9F87DA10-03A9-4B71-B2D5-1BE3FDA867C1Q40498431-0C0C8283-224E-4017-B058-C4617FC98DBCQ41513468-7B2CC5C7-DEE6-48E6-A0C8-3889B87DCAE8Q41648169-9E87418F-3E6C-48F5-9976-1090BD6E55F4Q50027655-9888DFB1-B418-4C02-90F2-2A4DFD449DBBQ52682421-23E99D7C-CA90-405A-8EF7-E99584E2213EQ54233532-A6D625A9-94FF-4ED6-9CF0-D051EE9049E6Q54265841-6D2F0A4E-749B-436A-8F9C-B911ABCB3F2BQ57168106-2B7F0F72-AB4B-4641-BE08-416819AA47AE
P2860
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A multi-component meningococca ...... clinical development program.
@en
A multi-component meningococcal serogroup B vaccine
@nl
type
label
A multi-component meningococca ...... clinical development program.
@en
A multi-component meningococcal serogroup B vaccine
@nl
prefLabel
A multi-component meningococca ...... clinical development program.
@en
A multi-component meningococcal serogroup B vaccine
@nl
P2093
P2860
P1433
P1476
A multi-component meningococca ...... clinical development program.
@en
P2093
Daniela Toneatto
James Wassil
Jeffrey Stoddard
Miguel O'Ryan
Peter M Dull
P2860
P2888
P356
10.1007/S40265-013-0155-7
P577
2014-01-01T00:00:00Z